Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

6.36
+0.39576.63%
Post-market: 5.79-0.5684-8.94%18:37 EDT
Volume:590.59K
Turnover:3.91M
Market Cap:3.48M
PE:-0.06
High:6.79
Open:5.95
Low:5.34
Close:5.96
52wk High:249.75
52wk Low:4.68
Shares:547.78K
Float Shares:547.42K
Volume Ratio:0.82
T/O Rate:107.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-102.4149
EPS(LYR):-337.9329
ROE:-705.71%
ROA:-127.92%
PB:0.70
PE(LYR):-0.02

Loading ...

Artelo advances ART26.12 into multiple ascending dose trial after Phase 1 safety data

Reuters
·
Apr 20

Alamar Biosciences Surges on Nasdaq Debut, Reaches $1.53 Billion Valuation

Deep News
·
Apr 18

Major US Stock Indices Climb Over 1%

Deep News
·
Apr 17

Artelo Biosciences Files Offering for 9.8 Million Common Stock; Shares Tumble

MT Newswires Live
·
Apr 08

Artelo Biosciences files to sell 9.82M shares of common stock for holders

TIPRANKS
·
Apr 08

Artelo Biosciences regains Nasdaq listing compliance after equity, annual meeting violations

Reuters
·
Apr 07

Artelo Biosciences Regains Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
Apr 07

Top Premarket Gainers

MT Newswires Live
·
Mar 31

Artelo Biosciences closes USD 11 million private placement priced at-market under Nasdaq rules

Reuters
·
Mar 31

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Mar 31

Top Premarket Decliners

MT Newswires Live
·
Mar 30

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

TIPRANKS
·
Mar 30

Top Midday Gainers

MT Newswires Live
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Artelo Biosciences announces $11.0 million private placement; shares price at $3.45 under Nasdaq rules

Reuters
·
Mar 27

Artelo Biosciences Announces $11.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Mar 27

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM

Reuters
·
Mar 27

Artelo announces expansion opportunity for ART27.13 in muscle preservation

TIPRANKS
·
Mar 26

Artelo Biosciences initiates non-clinical study of ART27.13 for GLP-1-related muscle loss; incretin market climbs to $200 billion by 2030 forecast

Reuters
·
Mar 26

Artelo Biosciences Expands Art27.13 Development as a Potential Companion Therapy to Glp-1 Treatments

THOMSON REUTERS
·
Mar 26